Environmental assessment of cytotoxic drugs in the Oncology Center of Cyprus.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
10
04
2019
accepted:
27
12
2019
entrez:
6
3
2020
pubmed:
7
3
2020
medline:
27
5
2021
Statut:
epublish
Résumé
Cytotoxic drugs constitute an important workplace hazard in the hospital environment. Our aim was to conduct an environmental assessment of hazardous drugs in the Oncology Center of Cyprus. Wipe samples were obtained from 42 workplace areas of the Oncology Center including two pairs of gloves in an initial assessment, while 10 samples were obtained at follow-up 3 years later. Potential contamination with cyclophosphamide (CP), ifosphamide (IF) and 5-fluorouracil (5-FU) and other cytotoxic medications was examined using the GC-MSMS system (CP, IF) and the HPLC system with UV detection (5-FU) method, respectively. Wipe sample contamination was detected at 11.9% and 15% in the initial and follow-up assessment, respectively. Both pairs of gloves assessed were free from contamination. The results showed contamination with cyclophosphamide on the work space inside the isolator, on a day-care office phone and on the central pharmacy bench. Ifosphamide was only detected on the floor of a patient's room. Contamination with 5-fluorouracil was found only on the surface of a prepared IV infusion bag. The levels of contamination in the positive samples ranged from 0.05 to 10.12 ng/cm2. The overall percentage of sample contamination at the Oncology Center was very low compared to other centers around the world. In addition, the detected levels of contamination with cytotoxic drugs were relatively low with the exception of the workspace inside the biological safety cabinet. These results in both assessments may reflect the implementation of comprehensive control measures including employee training, technological equipment and effective cleaning procedures.
Sections du résumé
BACKGROUND
Cytotoxic drugs constitute an important workplace hazard in the hospital environment. Our aim was to conduct an environmental assessment of hazardous drugs in the Oncology Center of Cyprus.
METHODS
Wipe samples were obtained from 42 workplace areas of the Oncology Center including two pairs of gloves in an initial assessment, while 10 samples were obtained at follow-up 3 years later. Potential contamination with cyclophosphamide (CP), ifosphamide (IF) and 5-fluorouracil (5-FU) and other cytotoxic medications was examined using the GC-MSMS system (CP, IF) and the HPLC system with UV detection (5-FU) method, respectively.
RESULTS
Wipe sample contamination was detected at 11.9% and 15% in the initial and follow-up assessment, respectively. Both pairs of gloves assessed were free from contamination. The results showed contamination with cyclophosphamide on the work space inside the isolator, on a day-care office phone and on the central pharmacy bench. Ifosphamide was only detected on the floor of a patient's room. Contamination with 5-fluorouracil was found only on the surface of a prepared IV infusion bag. The levels of contamination in the positive samples ranged from 0.05 to 10.12 ng/cm2.
CONCLUSIONS
The overall percentage of sample contamination at the Oncology Center was very low compared to other centers around the world. In addition, the detected levels of contamination with cytotoxic drugs were relatively low with the exception of the workspace inside the biological safety cabinet. These results in both assessments may reflect the implementation of comprehensive control measures including employee training, technological equipment and effective cleaning procedures.
Identifiants
pubmed: 32134912
doi: 10.1371/journal.pone.0216098
pii: PONE-D-19-10237
pmc: PMC7058296
doi:
Substances chimiques
Antineoplastic Agents
0
Cyclophosphamide
8N3DW7272P
Fluorouracil
U3P01618RT
Ifosfamide
UM20QQM95Y
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0216098Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Yakugaku Zasshi. 2010 Jun;130(6):903-10
pubmed: 20519870
J Oncol Pharm Pract. 2014 Apr;20(2):100-11
pubmed: 23676511
J Oncol Pharm Pract. 2012 Mar;18(1):23-36
pubmed: 21183556
CA Cancer J Clin. 2006 Nov-Dec;56(6):354-65
pubmed: 17135692
J Oncol Pharm Pract. 2011 Mar;17(1):20-8
pubmed: 20472603
Am J Health Syst Pharm. 2003 Nov 15;60(22):2314-20
pubmed: 14652980
J Occup Environ Med. 1995 Aug;37(8):957-61
pubmed: 8520960
Ann Work Expo Health. 2017 Oct 1;61(8):1003-1014
pubmed: 29028255
J Oncol Pharm Pract. 2012 Jun;18(2):201-6
pubmed: 21947739
J Chromatogr B Analyt Technol Biomed Life Sci. 2003 Jun 15;789(2):169-209
pubmed: 12742111
Arh Hig Rada Toksikol. 2018 Sep 1;69(3):238-249
pubmed: 30285944
J Oncol Pharm Pract. 2011 Mar;17(1):14-9
pubmed: 20179165
Am J Health Syst Pharm. 1999 Jul 15;56(14):1427-32
pubmed: 10428450
J Oncol Pharm Pract. 2014 Jun;20(3):210-6
pubmed: 23929731
Environ Monit Assess. 2017 Jan;189(2):52
pubmed: 28063118
J Oncol Pharm Pract. 2012 Mar;18(1):46-51
pubmed: 21737485
Ann Occup Hyg. 2005 Oct;49(7):629-37
pubmed: 16126760
Mutat Res. 2016 Oct - Dec;770(Pt A):35-45
pubmed: 27894689
J Oncol Pharm Pract. 2009 Sep;15(3):157-60
pubmed: 19171554
Ann Occup Hyg. 2005 Oct;49(7):619-28
pubmed: 16126757
J Oncol Pharm Pract. 2011 Mar;17(1):39-48
pubmed: 20156932
J Occup Environ Hyg. 2014;11(11):728-40
pubmed: 24766408
Pharm Weekbl Sci. 1992 Feb 21;14(1):16-22
pubmed: 1553250
J Occup Environ Med. 2014 Sep;56(9):901-10
pubmed: 25153300
Ann Occup Hyg. 2009 Mar;53(2):153-60
pubmed: 19261696
Am J Health Syst Pharm. 2018 Feb 15;75(4):199-211
pubmed: 29339374
J Oncol Pharm Pract. 2010 Mar;16(1):19-25
pubmed: 19965949
J Occup Environ Hyg. 2017 Mar;14(3):159-174
pubmed: 27676216
Anal Bioanal Chem. 2015 Sep;407(23):7083-92
pubmed: 26141324